Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
NCT03581747 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2018-09-10
Summary
The primary function of epithelial tissues is to form a barrier between the body and the external environment, in order to protect the internal tissues from environmental stresses, by minimizing water loss and preventing the entry of pathogens, pollutants and allergens. Allergic disorders, such as atopic dermatitis, have been associated to an impaired epithelial barrier function. Indeed, defects in the epithelial barriers allow tissue-damaging factors to enter the tissue and thus activate the immune response. This study aims to establish a method to assess the epithelial barrier function in vivo by electrical impedance (EI) spectroscopy, a new technique for the characterisation of epithelial tissue. By this technique, a harmless electrical signal is sent through the skin and the response of the tissue is analysed, which is influenced by several cellular properties, such as shape, orientation and size. In order to validate this technique, skin of mice was treated with some molecules able to destroy the epithelial barrier. The investigators observed that, after damaging the barrier, a decrease of the EI can be detected, consistent with the type and degree of the damage.
Based on this result, the investigators believe that this technique is a good candidate as an in vivo method to determine skin barrier defects, which might be used in the future as an early diagnostic tool for the prediction of the risk to develop atopic dermatitis in young subjects, allowing the possibility to apply in time possible preventive measures. In addition, this technique might be suitable for the evaluation of a given therapy during the hospitalisation. To confirm this hypothesis, in the present study patients with atopic dermatitis will be recruited. EI measurements will be performed in both lesional and non-lesional skin and values will be compared in order to detect any difference in the electrical response due to the inflammatory state. In addition, in order to evaluate whether these patients have an appreciable defect in their skin electrical behaviour, the investigators will compare non-lesional and lesional skin of patients with skin of healthy volunteers. Peripheral venous blood and skin biopsies will be collected, in oder to characterise several immune cell populations, to detect specific skin barrier mutations and to measure serum cytokines and immunoglobulins. These and some other parameters and will be analysed in order to identify a possible correlation with the EI.
Conditions
- Atopic Dermatitis
- Skin Inflammation
Interventions
- DEVICE
-
Nevisense
Measurement of electrical impedance
Sponsors & Collaborators
-
CK-CARE (Christine Kühne - Center for Allergy Research and Education)
collaborator UNKNOWN -
SciBase AB
collaborator OTHER -
Swiss Institute of Allergy and Asthma Research
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-08-01
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
- FDA Device
- Yes
Countries
- Switzerland
Study Locations
More Related Trials
-
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
NCT03059693 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
NCT00616096 ·Status: COMPLETED ·Phase: NA
-
Sodium in the Skin and Atopic Dermatitis
NCT06998446 ·Status: RECRUITING
-
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
NCT03901144 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Abrocitinib Treatment on Skin Barrier Function
NCT05140239 ·Status: ACTIVE_NOT_RECRUITING
-
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
NCT00863005 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Atopic Dermatitis (AD) and Food Allergy
NCT03168113 ·Status: COMPLETED
-
Effect of Moisturizing Creams on Skin Barrier Function
NCT00771121 ·Status: UNKNOWN ·Phase: PHASE4
-
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
NCT03945760 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
NCT03089229 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comprehending Atopic Risk Elements
NCT04325451 ·Status: UNKNOWN
-
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05999799 ·Status: TERMINATED ·Phase: PHASE2
-
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
NCT01149759 ·Status: COMPLETED ·Phase: NA
-
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878 ·Status: RECRUITING
-
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03989349 ·Status: COMPLETED ·Phase: PHASE3
-
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Different Skin Creams on TEWL
NCT03663673 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT05990725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Prospective Longitudinal Observational Research in Atopic Dermatitis
NCT04240522 ·Status: RECRUITING
-
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
NCT05983068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605 ·Status: RECRUITING
-
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
NCT05121480 ·Status: COMPLETED ·Phase: PHASE2
-
Short-term Topical Application to Prevent Atopic Dermatitis
NCT03871998 ·Status: COMPLETED ·Phase: NA